Archive · 9 Jun 2025
Lilly's Obesity Drug Sales Surge in India Amid High Demand
Eli Lilly, a US drug company, saw a big jump in sales of its weight-loss drug, Mounjaro, in India.
Sales went up 60% in May, reaching $1.5 million.
This is because many people in India are obese, and there's a high demand for solutions.
The demand is expected to keep rising.
Lilly's success is mirrored by rival Novo Nordisk set to launch soon.
Generic drug companies are also preparing to offer copycat treatments when patents expire.
The Indian government recently approved a generic version of a similar drug as well.
Eli Lilly's Mounjaro sales increased 60% in India in May.
Sales reached 126 million rupees ($1.5 million).
5 mg version sales more than doubled.
Demand for anti-obesity drugs is rising in India.
Biocon Ltd. received approval for a generic version of Novo Nordisk's Victoza.
- Who
- Eli Lilly & Co., Novo Nordisk, Biocon Ltd.
- What
- Increase in Eli Lilly's Mounjaro sales
- When
- Sales data for May 2025, launch in the second month.
- Where
- India
- Why
- High demand for anti-obesity solutions in India, where millions are affected by obesity and diabetes.
- Sales Increase (May)
- 60%
- Total Sales (May)
- $1.5 million
- Estimated Obese People in India
- 100 million
- Key Competitor
- Novo Nordisk
- Generic Approval
- Biocon Ltd.
